Sirius Tx

Sirius Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for cardiovascular and metabolic diseases. The company utilizes a proprietary siRNA discovery and delivery platform to develop long-acting therapies designed to improve patient compliance and outcomes. Its lead candidate, SR0441, is a Factor XI-targeting siRNA currently in Phase 1 clinical trials for the prevention of thrombotic events. Additionally, the company is advancing SR0447, which targets ANGPTL3 to treat dyslipidemia and hypertriglyceridemia. Sirius Therapeutics maintains a global presence with research and development facilities in both the United States and China. The company's mission is to provide innovative and accessible treatments for chronic conditions affecting millions worldwide.